Gynecologic oncology · 2008
Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study.
СтатьяПоддержка NIH: внешняя программаВалидационное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wenzel Lari, Huang Helen Q, Cella David, Walker Joan L, Armstrong Deborah K, Gynecologic Oncology Group
Аннотация
OBJECTIVE: To evaluate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Abdominal Discomfort (FACT/GOG-AD) subscale for assessing abdominal discomfort in patients undergoing treatment for ovarian cancer.
METHODS: A four-item questionnaire was developed for use in Gynecologic Oncology Group (GOG) protocol 172. It was administered to patients with advanced ovarian cancer treated on this protocol with intravenous (IV) cisplatin/paclitaxel or a combination of intravenous and intraperitoneal (IP) cisplatin/paclitaxel (IV/IP) prior to randomization, before cycle 4, 3-6 weeks after cycle 6, and 12 months after cycle 6. The subscale was evaluated in patients receiving IV/IP therapy for internal consistency, concurrent validity, sensitivity to treatment differences, and responsiveness to abdominal discomfort grading.
RESULTS: Internal consistency coefficients were 0.83 and 0.87 at baseline and pre-cycle 4 assessments, respectively; the average inter-item correlation was 0.61 at the pre-cycle 4 assessment. Item correlation with other scales ranged from 0.00-0.44. This subscale was able to distinguish those graded to have physician-rated abdominal pain compared to those without clinician-reported discomfort.
CONCLUSION: The four-item AD subscale reliably and validly assesses ovarian cancer-specific abdominal discomfort, and captures abdominal symptom responses to IV and IV/IP cisplatin/paclitaxel treatments.
METHODS: A four-item questionnaire was developed for use in Gynecologic Oncology Group (GOG) protocol 172. It was administered to patients with advanced ovarian cancer treated on this protocol with intravenous (IV) cisplatin/paclitaxel or a combination of intravenous and intraperitoneal (IP) cisplatin/paclitaxel (IV/IP) prior to randomization, before cycle 4, 3-6 weeks after cycle 6, and 12 months after cycle 6. The subscale was evaluated in patients receiving IV/IP therapy for internal consistency, concurrent validity, sensitivity to treatment differences, and responsiveness to abdominal discomfort grading.
RESULTS: Internal consistency coefficients were 0.83 and 0.87 at baseline and pre-cycle 4 assessments, respectively; the average inter-item correlation was 0.61 at the pre-cycle 4 assessment. Item correlation with other scales ranged from 0.00-0.44. This subscale was able to distinguish those graded to have physician-rated abdominal pain compared to those without clinician-reported discomfort.
CONCLUSION: The four-item AD subscale reliably and validly assesses ovarian cancer-specific abdominal discomfort, and captures abdominal symptom responses to IV and IV/IP cisplatin/paclitaxel treatments.